These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 22616372)

  • 1. [Statin therapy--for whom?].
    Kahri J; Syvänne M
    Duodecim; 2012; 128(8):811-8. PubMed ID: 22616372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of perioperative statin therapy for noncardiac surgery.
    Skrlin S; Hou V
    Semin Cardiothorac Vasc Anesth; 2010 Dec; 14(4):283-90. PubMed ID: 21041202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
    Ong HT
    QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit/risk ratio of statins in primary prevention.
    Reidenberg MM
    Clin Pharmacol Ther; 2008 Mar; 83(3):498-500. PubMed ID: 17538549
    [No Abstract]   [Full Text] [Related]  

  • 10. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES; Canavan ME; Desai MM
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins in primary prophylaxis of cardiovascular diseases].
    Kobalava ZhD; Villeval'de SV
    Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin therapy--Part II: Clinical considerations for cardiovascular disease.
    Sadowitz B; Seymour K; Costanza MJ; Gahtan V
    Vasc Endovascular Surg; 2010 Aug; 44(6):421-33. PubMed ID: 20547576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based use of statins for primary prevention of cardiovascular disease.
    Minder CM; Blaha MJ; Horne A; Michos ED; Kaul S; Blumenthal RS
    Am J Med; 2012 May; 125(5):440-6. PubMed ID: 22387091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
    Gotto AM
    Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
    [No Abstract]   [Full Text] [Related]  

  • 17. Statins, cardiovascular disease, and drug safety.
    Gotto AM
    Am J Cardiol; 2006 Apr; 97(8A):3C-5C. PubMed ID: 16581326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study].
    González-Juanatey JR; Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC
    Rev Esp Cardiol; 2011 Apr; 64(4):286-94. PubMed ID: 21411216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
    Whayne TF
    Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.